- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
REGN
VIE
Week ended 07 Aug 2026
Weekly Investor Report
Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
Latest close
673.6 EUR
5.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 9.8% above the Trend Line and sits at 89.8% of its 52-week range. The latest completed week returned 5.0%, after a 16.4% four-week move. The latest news-sentiment score is 48/100.
Setup score
48
out of 100
Latest Close
673.6 EUR
7 Aug 2026
1W Return
5.0%
latest completed week
4W Return
16.4%
short-term follow-through
12W Return
12.6%
quarterly tape
Trend Breadth
50.0%
26 of 52 weeks active
Volume Ratio
-
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
Price follow-through
5.0%
Latest completed week; four-week move 16.4%.
Indicator stack
28/70
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
48/100
18 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 9.8% above the Trend Line and sits at 89.8% of its 52-week range. The latest completed week returned 5.0%, after a 16.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is - the 13-week average. Participation data is incomplete.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1812-week average 0.19
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 16.4% over four weeks, 12.6% over 12 weeks, and 40.3% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year26
Trend breadth50.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.45Latest activity-pressure read.
Pressure change148.2%Four-week change in activity pressure.
Leadership-7.11Latest relative-leadership reading.
RS change61.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment48/100
Weighted news tone is neutral across 18 relevant articles.
4 positive · 12 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-3.4%Distance below the 52-week high.
13-week volatility4.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher14 of 2612 weeks finished lower.
Best week+10.2%Week of 31 Jul.
Worst week-8.5%Week of 22 May.
Latest week+5.0%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains10
Flat weeks0
Modest losses8
Sharp losses4
Recent vol4.7%13-week weekly-return volatility.
Base vol4.6%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAT Healthcare
4-week rank5 / 100
Group average2.6%
Trend breadth47.0%
Trend47.0%active weekly trend signals
MD73.0%positive activity pressure
RS10.0%positive relative leadership
Four-week leaders
IndustryAT Biotechnology
4-week rank1 / 21
Group average-4.6%
Trend breadth19.0%
Trend19.0%active weekly trend signals
MD42.9%positive activity pressure
RS4.8%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape41/100
Trend, activity pressure, participation, and risk combine to a 41/100 tape read.
Indicator analysis15/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.
Activity pressure 0.18; No reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment48/100Weighted news tone is neutral across 18 relevant articles.
NewEdge Advisors LLC Has $5.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 673.6 EUR | 5.0% | 613.4 EUR | 702.4 EUR | 0.45 | -7.11 | 0 | Off |
| 31 Jul 2026 | 641.7 EUR | 10.2% | 613.8 EUR | 702.7 EUR | 0.19 | -8.85 | 3 | Off |
| 24 Jul 2026 | 582.3 EUR | -2.4% | 614.4 EUR | 703.0 EUR | -0.23 | -17.36 | 0 | Off |
| 17 Jul 2026 | 596.7 EUR | 3.1% | 617.1 EUR | 703.6 EUR | -0.51 | -14.31 | 44 | Off |
| 10 Jul 2026 | 578.9 EUR | 1.2% | 618.9 EUR | 703.9 EUR | -0.94 | -18.55 | 194 | Off |
| 3 Jul 2026 | 571.8 EUR | 2.5% | 620.6 EUR | 704.3 EUR | -1.32 | -20.79 | 0 | Off |
| 26 Jun 2026 | 557.6 EUR | 4.9% | 622.1 EUR | 704.7 EUR | -1.48 | -21.07 | 0 | Off |
| 19 Jun 2026 | 531.5 EUR | 0.6% | 625.9 EUR | 705.2 EUR | -1.55 | -26.34 | 0 | Off |
| 12 Jun 2026 | 528.5 EUR | -4.1% | 629.7 EUR | 706.4 EUR | -1.50 | -23.88 | 0 | Off |
| 5 Jun 2026 | 551.0 EUR | 4.1% | 632.0 EUR | 707.6 EUR | -1.45 | -18.63 | 0 | Off |
| 29 May 2026 | 529.4 EUR | -3.3% | 632.1 EUR | 708.4 EUR | -1.43 | -22.74 | 10 | Off |
| 22 May 2026 | 547.6 EUR | -8.5% | 633.3 EUR | 709.4 EUR | -1.31 | -18.01 | 16 | Off |
| 15 May 2026 | 598.5 EUR | -1.0% | 631.6 EUR | 710.1 EUR | -1.16 | -8.92 | 16 | Off |
| 8 May 2026 | 604.6 EUR | 0.7% | 628.0 EUR | 710.8 EUR | -1.08 | -8.60 | 0 | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.